- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 9
- States / cities
- Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 6 more
Institution Directory
Clinical trials at Washington University School of Medicine
Sites in St. Louis, MO
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1747
Shown on this page
12
Current sort
Recently updated
Campus scope
Washington University School of Medicine, St. Louis, MO
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 469–480 of 1,747 matching trials with a site at Washington University School of Medicine, St. Louis, MO.
Live ClinicalTrials.gov results.
Live official records
Fimepinostat in Treating Brain Tumors in Children and Young Adults
NCT03893487
Site status not listed — check the official record
- Conditions
- Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
- Interventions
- Fimepinostat, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
NCT04305613
Site status not listed — check the official record
- Conditions
- Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
- Interventions
- Chemoradiation
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04929028
Site status not listed — check the official record
- Conditions
- AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 14
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147
Site status not listed — check the official record
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT03731260
Site status not listed — check the official record
- Conditions
- Indolent Systemic Mastocytosis
- Interventions
- Avapritinib, Placebo
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 15 more
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189
Site status not listed — check the official record
- Conditions
- Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
- Interventions
- SAT-3247, Placebo
- Drug
- Lead sponsor
- Satellos Bioscience, Inc.
- Industry
- Eligibility
- 7 Years to 9 Years · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT05612347
Status at this site: Recruiting
- Conditions
- Colorectal Polyp, Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer, Digestive System Disease
- Interventions
- FIT, Colonoscopy
- Diagnostic Test
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 65 Years to 82 Years
- Enrollment
- 6,434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Diego, California + 17 more
- Conditions
- High Risk Newly Diagnosed Multiple Myeloma
- Interventions
- Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 12
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652
Status at this site: Recruiting
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Interventions
- Zanubrutinib, Sonrotoclax, Computed Tomography, Bone Marrow Aspiration, Biospecimen Collection, Survey Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 180 more
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
NCT02595424
Site status not listed — check the official record
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Interventions
- Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 673
- States / cities
- Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
NCT06931340
Status at this site: Recruiting
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Androgen Therapy, Apalutamide, Docetaxel, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, PSMA PET Scan, Biospecimen Collection, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 213
- States / cities
- Tucson, Arizona • Dublin, California • Fremont, California + 172 more
About this Washington University School of Medicine institution page
- What this page lists
- ClinicalTrials.gov records that list Washington University School of Medicine in St. Louis, MO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, trials led by Washington University School of Medicine at any site, browse by condition, or browse by U.S. city.